Drug-eluting bead bronchial arterial chemoembolizati in SCLC | CMAR - Dove Medical Press
Introduction Small cell lung cancer (SCLC) is a rare but very lethal lung cancer type, and it is reported that the 5-year survival rate of SCLC patients is no more than 7%. 1,2 The majority of SCLC cases could be divided into two types: limited stage and extensive stage disease. Among these two types, the former is usually treated with chemotherapy, radiation, and surgery (suitable for a very small group of patients); as for the latter, only combined chemotherapy is the mainstay of treatment. 3,4 However, regarding the most crucial treatment for SCLC, there is a considerable portion of patients developing resistance to chemotherapy in the clinical setting. SCLC is sensitive to the first-line chemotherapy, cisplatin and etoposide; however, it often develops chemoresistance very quickly. 5,6 Moreover, many novel drugs are revealed to be inefficient in SCLC patients, such as the targeted drugs including sorafenib, gefitinib and so on. 7,8 Accordingly, novel therapy is urgently requi...